Upregulated serum L-FABP levels are related to the degree of hepatic fibrosis and inflammation, which indicates serum L-FABP can be a non-invasive marker to assess the severity of fibrosis and inflammation in NAFLD patients [79]. Here, FABP1 is linked to metabolic dysfunction-associated steatotic liver disease.